The rejection by the National Institute for Health and Clinical Excellence (NICE) of the Roche bowel-cancer drug Avastin (bevacizumab) as an NHS treatment may not be the end of the story.
The bevacizumab-based drug has been shown to shrink tumours in 78% of patients when added to chemotherapy drugs capecitabine and oxaliplatin.
It was rejected by NICE even after Roche had offered a patient-access scheme to reduce...
National Cancer Institute
NCI Cancer Bulletin
November 3, 2009 • Volume 6 / Number 21
The slow but steady march toward more individualized care in cancer medicine has left pancreatic cancer behind. Patients diagnosed with this disease live no longer today than patients diagnosed 2 decades ago, despite more than a dozen large clinical trials. Even as many patients with other cancers have benefited from targeted drugs like imatinib (Gleevec) and trastuzumab (Herceptin),...
Adding Capecitabine to Neoadjuvant Epirubicin and Docetaxel Offers Greater Response in Patients With Early Breast Cancer: Presented at ECCO-ESMO
Doctor's Guide: DGDispatch
By Chris Berrie
BERLIN -- October 1, 2009 -- Neoadjuvant epirubicin and docetaxel combined with capecitabine (EDC) provides significantly greater pathological complete response (pCR) over ED alone in treatment of patients with early breast cancer, and is feasible and safe, researchers stated...
Nexavar® in Combination with Chemotherapy Demonstrates 74 Percent Improvement in Progression-Free Survival
First presentation of results at joint ECCO-ESMO congress in Berlin, Germany
Abstract # 3LBA Berlin, September 23, 2009 – Bayer HealthCare AG and Onyx Pharmaceuticals, Inc. today announced the full results from their first collaborative group-sponsored randomized, double-blind, placebo controlled Phase II trial showing that Nexavar® (sorafenib tablets) in combination...
Avastin Plus Commonly Used Chemotherapies Improves Time Without The Disease Getting Worse In Women With Previously Treated Advanced Breast Cancer
Medical News Today
Date: 22 Aug 2009 - 2:00 PDT
Roche announced that a Phase III study of Avastin (bevacizumab) in combination with a range of chemotherapies met its primary endpoint of increasing the time women with previously treated advanced HER2 negative breast cancer lived without the disease getting worse (progression-free...
